Christopher M Reilly

List of Publications by Year in Descending Order

50 papers	3,461 citations	28 h-index	53 g-index
53 ext. papers	4,009 ext. citations	7.1 avg, IF	4.99 L-index

#	Paper	IF	Citations
50	Phenotypic Drift in Lupus-Prone MRL/lpr Mice: Potential Roles of MicroRNAs and Gut Microbiota.. *ImmunoHorizons*, **2022**, 6, 36-46	2.7	1
49	Regulation of neonatal IgA production by the maternal microbiota. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
48	EGR2 is elevated and positively regulates inflammatory IFN□production in lupus CD4 T cells. *BMC Immunology*, **2020**, 21, 41	3.7	0
47	Gut Microbiota and Bacterial DNA Suppress Autoimmunity by Stimulating Regulatory B Cells in a Murine Model of Lupus. *Frontiers in Immunology*, **2020**, 11, 593353	8.4	13
46	Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus. *Frontiers in Immunology*, **2020**, 11, 408	8.4	7
45	Pregnancy and lactation interfere with the response of autoimmunity to modulation of gut microbiota. *Microbiome*, **2019**, 7, 105	16.6	13
44	Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus. *Frontiers in Immunology*, **2019**, 10, 2512	8.4	15
43	Gut Microbiota in Human Systemic Lupus Erythematosus and a Mouse Model of Lupus. *Applied and Environmental Microbiology*, **2018**, 84,	4.8	125
42	Antibiotics ameliorate lupus-like symptoms in mice. *Scientific Reports*, **2017**, 7, 13675	4.9	64
41	Control of lupus nephritis by changes of gut microbiota. *Microbiome*, **2017**, 5, 73	16.6	144
40	Diet and Microbes in the Pathogenesis of Lupus **2017**,		2
39	Leaky Gut As a Danger Signal for Autoimmune Diseases. *Frontiers in Immunology*, **2017**, 8, 598	8.4	225
38	Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice. *Histology and Histopathology*, **2017**, 32, 1317-1332	1.4	6
37	Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. *Clinical Immunology*, **2016**, 162, 58-73	9	26
36	Cutting Edge: Plasmacytoid Dendritic Cells in Late-Stage Lupus Mice Defective in Producing IFN-□ *Journal of Immunology*, **2015**, 195, 4578-82	5.3	12
35	HDAC expression and activity is upregulated in diseased lupus-prone mice. *International Immunopharmacology*, **2015**, 29, 494-503	5.8	17
34	Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. *Clinical Immunology*, **2014**, 151, 29-42	9	54

33	Isoform-Selective HDAC Inhibition in Autoimmune DiseaseNicole L Regna1* and Christopher M Reilly2. *Journal of Clinical & Cellular Immunology*, **2014**, 05,	2.7	1
32	MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFB activation in vitro. *Cellular and Molecular Immunology*, **2014**, 11, 79-83	15.4	24
31	Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. *Environmental Toxicology*, **2013**, 28, 107-18	4.2	203
30	MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro. *Autoimmunity*, **2013**, 46, 351-62	3	25
29	Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. *Leukemia Research*, **2013**, 37, 112-6	2.7	11
28	Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. *International Immunopharmacology*, **2013**, 17, 894-906	5.8	28
27	Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection. *PLoS ONE*, **2013**, 8, e58431	3.7	60
26	Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. *PLoS ONE*, **2013**, 8, e54578	3.7	174
25	MicroRNAs implicated in the immunopathogenesis of lupus nephritis. *Clinical and Developmental Immunology*, **2013**, 2013, 430239		25
24	Immunomodulation and T helper TH/TH response polarization by CeO and TiO nanoparticles. *PLoS ONE*, **2013**, 8, e62816	3.7	65
23	A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production. *Experimental Hematology*, **2012**, 40, 622-33	3.1	4
22	HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-B pathways. *Inflammation Research*, **2012**, 61, 521-33	7.2	38
21	Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. *Cellular and Molecular Immunology*, **2012**, 9, 255-66	15.4	36
20	HDAC inhibition in lupus models. *Molecular Medicine*, **2011**, 17, 417-25	6.2	44
19	Combined cytotoxic and anti-invasive properties of redox-active nanoparticles in tumor-stroma interactions. *Biomaterials*, **2011**, 32, 2918-29	15.6	169
18	Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. *Journal of Biological Chemistry*, **2011**, 286, 28833-28843	5.4	70
17	Deletion of PPAR- in immune cells enhances susceptibility to antiglomerular basement membrane disease. *Journal of Inflammation Research*, **2010**, 3, 127-34	4.8	5
16	Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. *Cellular and Molecular Immunology*, **2010**, 7, 123-32	15.4	68

15	Anti-inflammatory properties of cerium oxide nanoparticles. *Small*, **2009**, 5, 2848-56	11	511
14	Protonated nanoparticle surface governing ligand tethering and cellular targeting. *ACS Nano*, **2009**, 3, 1203-11	16.7	76
13	The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. *Journal of Autoimmunity*, **2008**, 31, 123-30	15.5	87
12	AICAR inhibits inflammation in MRL/lpr mouse mesangial cells. *FASEB Journal*, **2008**, 22, 942.12	0.9	
11	Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. *European Journal of Pharmacology*, **2007**, 567, 67-76	5.3	7
10	Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. *European Journal of Immunology*, **2006**, 36, 1296-308	6.1	36
9	Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. *Journal of Immunology*, **2004**, 173, 4171-8	5.3	131
8	Hematopoietic origin of glomerular mesangial cells. *Blood*, **2003**, 101, 2215-8	2.2	160
7	Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. *Journal of Clinical Investigation*, **2003**, 111, 539-52	15.9	314
6	Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. *Arthritis and Rheumatism*, **2002**, 46, 598-605		29
5	Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. *Kidney International*, **2002**, 61, 839-46	9.9	46
4	Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. *Immunologic Research*, **2002**, 25, 143-53	4.3	41
3	Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. *Journal of Immunology*, **2001**, 166, 6444-51	5.3	124
2	Prostaglandin J(2) inhibition of mesangial cell iNOS expression. *Clinical Immunology*, **2001**, 98, 337-45	9	52
1	Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. *Journal of Immunology*, **2000**, 164, 1498-504	5.3	68